- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.12.23 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 15.12.2023 | 667 | Xetra Newsboard | The following instruments on XETRA do have their first trading 15.12.2023 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 15.12.2023
Aktien
1 CA02255Q2099 Alvopetro Energy Ltd.
2... ► Artikel lesen | |
| 14.12.23 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 14.12.2023 | 544 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 14.12.2023Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 14.12.2023ISIN NameAT0000A1PY49 CLEEN... ► Artikel lesen | |
| 14.12.23 | XFRA ISIN CHANGE | 657 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen CA13646R5096 Canadian Palladium Resources Inc. 14.12.2023 CA74840A1066 Canadian Palladium Resources Inc. 15.12.2023... ► Artikel lesen | |
| 19.09.23 | Guard Therapeutics reports robust efficacy of RMC-035 in Phase 2 (AKITA) and advances clinical development program | 73 | GlobeNewswire (Europe) | Statistically significant and clinically relevant improvement of long-term kidney function (compared to placebo)Statistically significant and clinically relevant reduction of Major Adverse Kidney Events... ► Artikel lesen |
4 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 52,40 | +1,51 % | NASDAQ OMX Nordic: Change of name and ticker code for Novozymes (97/24) | The Extraordinary General Meeting (EGM) of Novozymes A/S (Novozymes) held on
March 4, 2024 approved a secondary name of the company Novonesis A/S. As a
consequence of the name change, Novozymes has... ► Artikel lesen | |
| GENMAB | 268,20 | -1,32 % | Genmab's Q1 Darzalex Sales By Johnson & Johnson Reach $2.692 Bln | NEW BRUNSWICK (dpa-AFX) - Genmab A/S (GMAB), a Danish biotechnology firm, announced on Tuesday that the first-quarter sales of Darzalex, Daratumumab, have totaled $2.692 billion, as updated... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 2,438 | -1,85 % | Arbutus Biopharma Corporation: Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update | ||
| MOLECULIN BIOTECH | 4,100 | 0,00 % | Moleculin Biotech, Inc.: European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) | - Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine achieves preliminary CRc rate of 60% in 2nd line AML subjects... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 2,780 | +4,08 % | BioXcel Therapeutics, Inc. - 8-K, Current Report | ||
| SENSEI BIOTHERAPEUTICS | 0,894 | -0,45 % | Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment | BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics... ► Artikel lesen | |
| VERICEL | 42,400 | -0,93 % | Vericel Corporation: Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance | Full-Year 2023 Total Revenue Growth of 20% to $197.5 Million, with Adjusted EBITDA Growth of 40% Fourth Quarter Total Revenue Growth of 23% to $65.0 Million, with Adjusted EBITDA Growth of 50% Fourth... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,712 | -1,11 % | MustGrow Biologics Corp.: MustGrow Biologics to Present at the Planet MicroCap Showcase | MustGrow Biologics to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024Saskatoon, Saskatchewan--(Newsfile Corp. - April 17, 2024)... ► Artikel lesen | |
| AKEBIA | 1,272 | -0,70 % | Akebia Therapeutics, Inc. - 8-K, Current Report | ||
| REGENXBIO | 14,600 | -0,68 % | REGENXBIO Inc.: Regenxbio Announces New Positive Initial Efficacy Data From Affinity Duchenne Trial | New three-month assessment in first patient at dose level 2 demonstrates robust microdystrophin expression
Patient aged 12 years at dosing had expression level at 75.7% of control
Early evidence... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 8,600 | +0,58 % | FENC breaks ground on expansion of green PET production facility | ||
| ZEVRA THERAPEUTICS | 4,240 | -0,93 % | Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting | The oral presentation highlighted data from Zevra's Expanded Access Program demonstrating a consistent safety profile CELEBRATION, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc.... ► Artikel lesen | |
| REVANCE THERAPEUTICS | 3,400 | -0,58 % | OPI, RVNC and AQST are among after hour movers | ||
| CORVUS PHARMACEUTICALS | 1,292 | -3,87 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis | Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company's selective ITK inhibitor Corvus anticipates releasing initial clinical data from... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 18,660 | +12,82 % | Cartesian Therapeutics, Inc. - 8-K, Current Report |
Das Unternehmen GUARD THERAPEUTICS INTERNATIONAL AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -5,30 % bei einem Aktienkurs von 2,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
